Under the Radar, page-164

...and therein lies the ahz dilemma...ahz is no longer a biotech company reliant on CR's to fund a unicorn...those perceptions for some reason seem to linger...but not for much longer imo, particularly if and when a Vax deal is done...

..ahz is now a fully fledged, focused, medical device technology company...

...it is developing (amongst others) a unique product for the most important organ in the body, a product described as a world first, is calcium free, robust that will potentially become a clear leader in a market expected to to virtually double in two years to US$5B alone....how much will this market be worth in 5 or 10 years time?

...WP (and his team), have everything in place to capture the lions share of this market in the future...

..for me as a forward thinking investor, confident that ahz will be successful in commercialising it's TAVR device, there has never been a better time to invest

...imo, the opportunity to take advantage of a sluggish share price that i believe significantly undervalues ahz may just represent the opportunity of a lifetime...